<u>Heart Failure:</u> <u>Pathophysiology, Diagnosis,</u> <u>and Hemodynamic Targets</u>

<u>Alan</u> <u>Maisel</u> <u>MD</u>


Professor of Medicine, University of California, San Diego



Heart Failure Rages Through American Cities



The Boys Go Out For A 'Heart Healthy' Lunch...



And Then Walk the Dog For Exercise



Acute Heart Failure Magnitude of the Problem

- 1 million admissions annually in the U.S. (750%) over the past 10 years)
- Most common admitting diagnosis for patients ≥ 65 years
- Hospitalization costs are considerable
 (>60% of amount spent on heart failure)

Acute Heart Failure Have We Made Progress?


• The good news:

- \Box In-hospital mortality 5% ($\checkmark 40\%$ in 10 years)
- □ Mean length of stay 5-6 days ($\sqrt{30\%}$ in 10 years)

• The bad news:


- □ Readmission rates remain high
 - 25% within 30 days
 - 50% within 6-12 months
- □ High mortality rates persist
 - 5-10% at 30 days
 - 20-40% at 6-12 months

HCFA Hospitalization Costs




O' Connell JB, et al. J Heart Lung Transplant. 1994;13:S107-S112.

Worsening Chronic Heart Failure Is the Major Reason for Heart Failure Hospitalizations



Fonarow GC. *Rev Cardiovasc Med.* 2003;4 (suppl 7):S21-S30. Cleland JG, et al. *Eur Heart J.* 2003;24:442.

Compliance with medications



<u>Compliance with</u> <u>a low-salt diet</u>

Acute Decompensated Heart Failure:			
Patient Characteristics			
	ADHERE	OPTIMIZE-HF	Euro-HF
	N = 105,388	N = 48,612	N = 11,327
Mean age (yrs)	72.4	73	71
> 75 years (%)	50	ND	30 men
			51 women
Male (%)	48	48	53
Caucasian (%)	72	ND	ND
Prior HF history (%)	75	87	65
Systolic dysfunction (%)	54	46	45

Adams KF, et al. Am Heart J. 2005;149:209-216. Gheorghiade M. Circulation. 2005;112:3958-3968. Cleland JG, et al. Eur Heart J. 2003;24:442-463.

Heart Failure as a Symptomatic Disorder Functional Class

NYHA

Class I: normal exercise tolerance
 Class II: symptoms with ordinary exertion
 Class III: symptoms with only mild exertion
 Class IV: symptoms at rest

Problem: the underlying disease progresses, even in the absence of symptoms!!

Rationale for a New Way of Classifying Patients With HF in 2009

- HF represents a continuum beginning with risk factors and culminating in end-stage or refractory disease
- There are known risk factors and structural prerequisites leading to the development of LV systolic and/or diastolic dysfunction and the clinical syndrome of HF
- HF is a preventable disorder



At high risk of HF but without structural heart disease or HF symptoms





Structural heart disease but without signs or symptoms of HF

Stage B

At high risk of HF but without structural heart disease or HF symptoms

Stage A



Structural heart disease with prior or current HF symptoms



Structural heart disease but without signs or symptoms of HF

Stage B

At high risk of HF but without structural heart disease or HF symptoms

Stage A



Refractory HF requiring specialized interventions

Stage D

Structural heart disease with prior or current HF symptoms **Stage C**

Structural heart disease but without signs or symptoms of HF

Stage B

At high risk of HF but without structural heart disease or HF symptoms

Stage A

The Cardiovascular Disease Continuum

Endothelial Dysfunction

Pathological Remodeling (LVH)

Vascular Disease (Atherosclerosis)

Endothelial Dysfunction

Risk Factors: Obesity, Insulin Resistance Heart Attack (Myocardial Dysfunction) Maladaptive Remodeling

Left Ventricular Enlargement

Heart Failure

DEATH

Adapted from Dzau V et al. Am Heart J 1991;121:1244-63.

Heart Failure: A Changing Paradigm

1950's - 1980's

Hemodynamic Model

- Reduced contractility, pump dysfunction
- Treatment:
 - Positive inotropic drugs to stimulate contractility
 - Vasodilators to "unload" the heart
 - Conventional drugs
 - Diuretics
 - Digitalis

1980's - 2004

Neurohormonal Model

- Progressive remodeling with impaired myocardial performance
- Treatment:
 - Prevention of progression with neurohormonal blockers:
 - ACE inhibitors, aldo blockers
 - β-adrenergic blockers,ARBs
 - Conventional drugs
 - Diuretics
 - Digitalis
 - Emerging therapies
 - Bi-Ventricular Pacing
 - Bi-V Pacing + ICD
 - LV Reconstruction surgery (Dor)
 - Acorn, Myosplint

Structural Remodeling Post-MI


<u>Days</u>



<u>MI due to</u> <u>coronary</u> <u>occlusion</u>



Scarring and reshaping of the heart (remodeling) Months - Years



<u>Heart enlarges and</u> <u>leads to congestive</u> <u>heart failure</u>

Remodeling Is The Major Cause of Progressive Cardiac Dysfunction



6 months post-MI

14 months post-MI



Structural heart disease but without signs or symptoms of HF

Stage B

At high risk of HF but without structural heart disease or HF symptoms

Stage A



Structural heart disease with prior or current HF symptoms



Structural heart disease but without signs or symptoms of HF

Stage B

At high risk of HF but without structural heart disease or HF symptoms

Stage A



Refractory HF requiring specialized interventions

Stage D

Structural heart disease with prior or current HF symptoms **Stage C**


Structural heart disease but without signs or symptoms of HF

Stage B


At high risk of HF but without structural heart disease or HF symptoms

Stage A


Role of Neurohormonal Activation in Remodeling



ACE = angiotensin-converting enzyme; ANP = atrial natriuretic peptide; BNP = B-type natriuretic peptide; RAAS = renin-angiotensin-aldosterone system Cohn JN, et al. *J Am Coll Cardiol.* 2000;35(3):569–582.




Progression of Heart Failure




CAD = coronary artery disease; CMP = cardiomyopathy; HTN = hypertension; LV = left ventricular; RAAS = reninangiotensin-aldosterone system; SNS = sympathetic nervous system Greenberg BH. *Hosp Physician.* 2002;38(1):43-49.

Pathophysiologic Effects of Angiotensin II



Effects of CHF on Renal Function



The Cardio-Renal Syndrome of Heart Failure

Decreased cardiac performance

Increased water & Na⁺ retention

Impaired renal function



Decreased cardiac output

Neurohormonal Activation

Diminished blood flow

Decreased renal perfusion

Diagnosis of Heart Failure

Alan Maisel MD

Professor of Medicine, University of California, San Diego



Director Coronary Care Unit And Heart Failure Program San Diego Veterans Hospital

Case- MA- 1

- HPI: 65 year old male was visiting relatives in San Diego when over the course of 24 hours he developed progressively worsening dyspnea, occurring first with minimal exertion and culminating with shortness of breath at rest. He denied any chest pain or nausea but said he felt his heart skipping some beats.
- **PMH**: Hypertension, COPD, remote myocardial infarction. He was told he had a normal "ejection fraction" one year ago.

MA-2

- Meds: Two inhalers, clonidine, simvistatin
- PE: vitals: 170/100-100-26; JVP-14 cm, rhonchi and wheezing throughout all lung fields. No gallops or edema.
- ECG: sinus tachycardia, multifocal pacs, LVH, LAE and old Q waves inferiorly.
- **CXR**: (poor quality) no cardiomegally. Possible cephalization.
- Bedside echo (fellow): mild inferior wall hypokinesis (old). Overall systolic function was normal.

MA- Questions-a

- What is the diagnosis?
- How can you differentiate between COPD and CHF?
- If this is CHF, what has precipitated it?
- What other tests would you order?



Labs:
 TnI <0.4
 CBC normal
 Electrolytes: normal
 BNP: not done

MA-4

The diagnosis was COPD exacerbation.

- He was given oxygen, nebulization treatments, and a steroid bolus.
- He felt slightly better and was discharged home two hours later at 8pm.

Goals in Diagnosis



- For your mother
 - □ Rapid
 - □ Highly accurate
 - □ Non-invasive, if at all possible
 - □ Spare no expense


Goals in Diagnosis



- For your mother-in-law
 - □ No rush
 - □ Mistakes happen
 - □ Invasive studies, got no problem with that
 - □ She is cheap, don't go wasting money

The Short of Breath Pie






We need to make rapid, accurate diagnoses and triage patients accordingly



The Hall and the physical exam



The Challenge of Diagnosing Heart Failure: Physical Examination

JVP on Physical Exam

Great if well seen

In OPTIMIZE and ADHERE, in the majority of hospitalized HF patients, initial exam missed it

Obesity epidemic: good luck

S3 on Physical Exam

Great if heard


Missed 4/5 times




How Good Is the History and Physical in AHF?

Variable	Sensitivity (%)	Specificity (%)	Accuracy (%)
Hx of HF	62	94	80
Dyspnea	56	53	54
Orthopnea	47	88	72
Rales	56	80	70
S3	20	99	66
JVD	39	94	72
Edema	67	68	68

Chest X-Ray in Heart Failure




The CXR is not all it's cracked up to be



- Misses 20% of echo proven cardiomegaly
- Detection of pleural effusion if supine
 - 67% sensitivity
 - 70% specificity
- Even worseif done portable

How sure are we about the diagnosis of CHF?





Adapted with permission from McCullough, Maisel et al. *Circulation.* 2002;106:416-422.

The Challenge of Diagnosing Heart Failure


* Primary care diagnosis

Correct diagnosis on initial presentation 18% of females 36% of males Emergency department diagnosis 12% entirely wrong diagnosis 6% over diagnosed 6% under diagnosed

Cardiorenal Axis

ANP, BNP, and CNP


- Natriuretic
- Diuretic
- Vasodilating
- Renin and aldosterone inhibiting
- Anti-fibrotic




Renin-angiotensinaldosterone system

- Sodium retaining
- Antidiuretic
- Vasoconstricting
- Fibrosis










BNP & NT ProBNP: They Look Similar But May Be "Different Animals"



BNP and NT-proBNP Summary

- BNP is a more widely used marker
- Values of the two molecules are NOT interchangeable
- **Both are good diagnostic markers in heart failure**
- Diagnostic algorithms and cut-offs are more complex for NT-proBNP than for BNP
- Both can be used to screen for LV dysfunction
- **Both are good prognostic markers in heart failure**
- NT-proBNP values appear to be more effected by renal function
- **BNP** is a more dynamic marker due to differences in half-lives

The Cardiovascular Disease Continuum



Adapted from Dzau V et al. Am Heart J 1991;121:1244-63.

Breathing Not Properly STUDY

The New England Journal of Medicine

Copyright © 2002 by the Massachusetts Medical Society

VOLUME 347

JULY 18, 2002

NUMBER 3



RAPID MEASUREMENT OF B-TYPE NATRIURETIC PEPTIDE IN THE EMERGENCY DIAGNOSIS OF HEART FAILURE

Alan S. Maisel, M.D., Padma Krishnaswamy, M.D., Rich, Judd E. Hollander, M.D., Philippe Duc, M.D., Torbjøf William T. Abraham, M.D., Alan H.B. Wu, Ph.D., Arne Westheim, M.D., Ph.D., M.P.H., Catherine Radmila Kazanegra, M.D., Howard C. Herrmann, N for the Breathing Not Properly Mul


Clinical Investigation and Reports

B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure Analysis From Breathing Not Properly (BNP) Multinational Study


RT

Peter A. McCullough, MD, MPH; Richard M. Nowak, MD, MBA; James McCord, MD; Judd E. Hollander, MD; Howard C. Herrmann, MD; Philippe G. Steg, MD; Philippe Duc, MD; Arne Westheim, MD, PhD; Torbjørn Omland, MD, PhD, MPH; Cathrine Wold Knudsen, MD; Alan B. Storrow, MD; William T. Abraham, MD; Sumant Lamba, MD; Alan H.B. Wu, PhD; Alberto Perez, MD; Paul Clopton, MS; Padma Krishnaswamy, MD; Radmila Kazanegra, MD; Alan S. Maisel, MD; for the BNP Multinational Study Investigators

Specificity, Sensitivity, and Accuracy of BNP Cutoff Value




Clarification of Diagnosis & BNP



Indecision

Acute Dyspnea: BNP ROC Curve



McCullough, Maisel et al., Circulation 2002 106:416-42

Results of the BNP for Acute Shortness of Breath Evaluation (BASEL) Study

End Point	Routine Assessment	Routine Assessment	<i>P</i> Value
	(n=227)	+ BNP (n=225)	<i>r</i> value
Time to treatment	90	63	0.03
(minutes, median, interquartile range)	(20-205)	(16-153)	
Time to discharge	11.0	8.0	0.001
(days, median, interquartile range)	(5.0-18.0)	(1.0-16.0)	
Hospitalization (%)	85	75	0.008
Intensive-care unit admission (%)	24	15	0.01
Total treatment cost	7264	5410	0.006
(S. median, 95% confidence intervals)	(6301-8227)	(4516-6304)	
In-hospital mortality (%)	9	6	0.21
30-d mortality (%)	12	10	0.45

Mueller C et al. N Engl J Med 2004;350:647-54.

Caveats to NP testing




- Gray Zone
- Renal dysfunction
- Obesity
- Heart Failure with normal levels

"Grey Zone" BNP

Usually from Right Ventricle

- Pulmonary disease
 - **COPD** with cor pulmonale
 - **pulmonary hypertension**
- Right ventricular failure
 - □ from long-standing left ventricular failure
 - □ right ventricular infarction
- Pulmonary embolism
- Knowledge of baseline BNP levels are important



Renal dysfunction



- NP are retained in patients with renal dysfunction
- Level much higher in HF with same amt of renal dysfunction
- Need to know baseline values
- Even in dialysis patients- NP above baseline might represent volume overload







- There appears to be a linear inverse relationship between BMI and NP levels
- Patients who are obese (BMI >30kg/m²) should have their NP doubled to use the standard cutpoints.




- 63 year old non-obese man with history of coronary artery disease and bypass surgery 6 years ago
- Complains that he has had leg swelling for several years and is now developing abdominal pain
- Physical exam with elevated JVP, hepatomegaly and ascites with a third heart sound
- Echo reveals normal right and left ventricular function
- BNP 84 pg/ml

Why is the BNP level low?

- This is a falsely negative BNP. This patient has heart failure.
- The right ventricle makes BNP when overloaded, so this is a false negative reading.
- The patient has neither left nor right heart failure.
 Another test is in order.

Constrictive pericarditis





The presence of pericardial calcification on chest x-ray strongly suggests pericardial constriction in patients with symptoms of heart failure.

Normal levels of BNP

Heart failure

- Flash pulmonary edema
- Acute atrial fibrillation
- Acute papillary muscle rupture
- Mitral stenosis

Looks like HF but not!
Tamponade
Pericarditis

IN ACS--Time Is Myocardium!


So we strive to shorten door to balloon time



So in Acute Decompensated Heart Failure, why don't we strive to improve door to Diuretic time!!



Sunday in the ER Is speed important?




Turnaways and huge delays are a surefire recipe for disaster. What you can do






Delayed BNP Equals Delayed Treatment



Maisel, Peacock, Fonarow, Jesse et al JACC 2008


% Rales vs. Quartiles of Diuretic Time & BNP Level



Time to diuretic

Maisel, Peacock, Fonarow, Jesse et al JACC 2008

Mortality (%)




Time to IV Diuretic (hours)

Lets talk about things that lead to a bad pronosis



There is no cardiac biomarker that is as good as a NP level for prognosis








- Multicenter blinded BNP study N= 464, 90% admitted
 If admitted: 11% with BNP < 200
 90 day events (CHF visit, admit, death) 9% if BNP < 200 29% if BNP > 200
- Disconnect between perceived severity and BNP

Maisel AS, JACC. 2004 Sep 15;44(6):1328-33

REDHOT BNP Values & Patient Disposition



- Previous data link high BNP to morbidity & mortality
- Actual BNP values blinded to ED physician
- BNP median values

 ~22% higher in patients discharged home from ED



Maisel AS et al. In Press.

MA-5

- At 11 pm that same night, he awoke with severe shortness of breath. His wife called 911 and he was brought back to the same emergency room (different physician).
- PE: 160/110- pulse-140 (irregular)-26. O₂ sat = 88%. Lungs: Poor air movement. The monitor showed atrial fibrillation.

MA-questions b

 What is going on? COPD Pulmonary embolism CHF If CHF- what kind and why?

- What test(s) might be helpful at this point?
 - □ Cardiac markers
 - □ D-dimer
 - □ Lower extremity dopplers
 - □ BNP

MA-questions c

The BNP level was 900 pg/ml
What is going on and why?
How would you treat this patient?

MA-6

- He was brought to the ICU where he was given lasix 40 mg ivp, diltiazem 10 mg/hour iv (heart rate control) and Natrecor 2mcg/kg bolus followed by .01 mcg/kg/min infusion.
- Twenty four hours later he felt much better. His heart rate was back in NSR. His lungs were clear. He had diuresed 3 liters of fluid. Four hours after the discontinuation of Natrecor his BNP level was 150 pg/ml.

MA-7

- Full doppler echocardiographic exam revealed diastolic dysfunction with E/A < .7 and Deceleration time 320 ms (impaired relaxation).
- He was placed on an ACE inhibitor and beta blocker and discharged 2 days later.

MA-8- final points

- Patient had COPD with underlying diastolic dysfunction.
- Atrial fibrillation led to severe CHF.
- A BNP level was able to help separate CHF from COPD exacerbation
- Diastolic function is common in the emergency room.
- BNP is elevated in diastolic dysfunction

Assessment of Patient with Dyspnea

For Your Mother

- History, physical exam by top gun attending
- Pulse oximetry
- **ECG within 5 minutes**
- CBC, chem panel
- BNP or NT-pro BNP
- **Troponin**
- **D**-dimer, if indicated
- CXR PA and Lateral
- Other testing and imaging as indicated

Mother-in-law

- Wait in a side room for a few hours
- History, physical exam by 1st year med student
- ABG
- CBC, chem panel
- Portable CXR

